Everything below concerns CJC-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Other cells Various other abnormal cells may be present in the blood in certain conditions. For example, lymphoma cells may be found on the manual differential in some cases of lymphoma, and in mast cell leukaemia, mast cells, which are normally confined to tissue, circulate in the blood. There is a very rare phenomenon called carcinocythemia in which tumour cells are seen on the peripheral blood smear.
RCH(NHP)CO2H + R'CH(NH2)CO2CH3 → RCH(NHP)C(O)NH(CHR')CO2CH3 + H2O Subsequent to this coupling reaction, the amine protecting group P and the ester are converted to the free amine and carboxylic acid, respectively. For many amino acids, the ancillary functional groups are protected. The condensation of the amine and the carboxylic acid to form the peptide bond generally employs coupling agents to activate the carboxylic acid. The Bergmann azlactone peptide synthesis is a classic organic synthesis for the preparation of dipeptides.
Ground substance is an amorphous gel-like substance in the extracellular space of animals that contains all components of the extracellular matrix (ECM) except for fibrous materials such as collagen and elastin. Ground substance is active in the development, movement, and proliferation of tissues, as well as their metabolism. Additionally, cells use it for support, water storage, binding, and a medium for intercellular exchange (especially between blood cells and other types of cells). Ground substance provides lubrication for collagen fibers. The components of the ground substance vary depending on the tissue. Ground substance is primarily composed of water and large organic molecules, such as glycosaminoglycans (GAGs), proteoglycans, and glycoproteins. GAGs are polysaccharides that trap water, giving the ground substance a gel-like texture. Important GAGs found in ground substance include hyaluronic acid, heparan sulfate, dermatan sulfate, and chondroitin sulfate. With the exception of hyaluronic acid, GAGs are bound to proteins called proteoglycans. Glycoproteins are proteins that attach components of the ground substance to one another and to the surfaces of cells. Components of the ground substance are secreted by fibroblasts. Usually it is not visible on slides, because it is lost during staining in the preparation process. Link proteins such as vinculin, spectrin and actomyosin stabilize the proteoglycans and organize elastic fibers in the ECM. Changes in the density of ground substance can allow collagen fibers to form aberrant cross-links.
The physiological role for responses to these, and several other glycoprotein hormones, is not fully understood, although it is likely that ACTH is bifunctional, like PTH, supporting bone formation with periodic spikes of ACTH, but causing bone destruction in large concentrations. In mice, mutations that reduce the efficiency of ACTH-induced glucocorticoid production in the adrenals cause the skeleton to become dense (osteosclerotic bone).
Collagen XVII, previously called BP180, is a transmembrane protein which plays a critical role in maintaining the linkage between the intracellular and the extracellular structural elements involved in epidermal adhesion, identified by Diaz and colleagues in 1990. COL17A1 is the official name of the gene. It encodes the alpha chain of type XVII collagen. Collagen XVII is a transmembrane protein, like collagen XIII, XXIII and XXV. Collagen XVII is a structural component of hemidesmosomes, multiprotein complexes at the dermal-epidermal basement membrane zone that mediate adhesion of keratinocytes to the underlying membrane. It also appears to be a key protein in maintaining the integrity of the corneal epithelium. Mutations in this gene are associated with both generalized atrophic benign and junctional epidermolysis bullosa, as well as recurrent corneal erosions, and expression of this gene is abnormal in various cancers. Two homotrimeric forms of type XVII collagen exist. The full length form is the transmembrane protein. A soluble form, referred to as either ectodomain or LAD-1, is generated by proteolytic processing of the full length form.
Sources: en.wikipedia.org
Ueda left Sony in December 2011, although he remained under contract to finish work on The Last Guardian. Around mid-2014, he formed GenDesign (stylized as genDESIGN), made up of former members from his team to help complete development of The Last Guardian. At E3 2015, The Last Guardian was announced for release on October 25, 2016, but was later delayed to December 6, 2016. In September 2018, Ueda revealed that the studio was at the prototyping stage of designing a new game, supported with funding from the investment fund Kowloon Nights. In March 2020, Epic Games announced that they would be fully funding development, with the two companies splitting profits in half. At the 2024 Game Awards the first teaser for the game was revealed, then codenamed "Project Robot". The full title, genATLAS, was revealed at Summer Game Fest 2026, alongside the first full trailer.
=== Deka Base === The Deka Base (デカベース, Deka Bēsu) is the primary headquarters and base of operations of the S.P.D. Earth unit. It is equipped with Base Beams (ベースビーム, Bēsu Bīmu) and houses the Deka Machines. Additionally, the Deka Base can transform into either the Deka Base Crawler (デカベースクローラー, Deka Bēsu Kurōrā), which is equipped with the Crawler Beam (クローラービーム, Kurōrā Bīmu) cannons, or the humanoid Deka Base Robo (デカベースロボ, Deka Bēsu Robo), which is equipped with Finger Missiles (フィンガーミサイル, Fingā Misairu) and Knee Brace Beams (ニーブレスビーム, Nī Buresu Bīmu). Deka Base Robo's finisher is the Volcanic Buster (ヴォルカニック・バスター, Vorukanikku Basutā). As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, the Deka Base has been rebuilt and renamed the Neo Deka Base (ネオデカベース, Neo Deka Bēsu). As of the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster, the Neo Deka Base has been rebuilt and renamed the Shin Neo Deka Base (シン・ネオデカベース, Shin Neo Deka Bēsu).
Certain regions of an organism's genome will be more or less likely to undergo mutation depending on the presence of DNA repair mechanisms and other mutation biases. For instance, in a study on Arabidopsis thaliana, biologically important regions of the plant's genome were found to be protected from mutations, and beneficial mutations were found to be more likely, i.e. mutation was "biased in a way that benefits the plant". Mammals did not evolve from any modern group of reptiles; rather, mammals descend from a Reptiliomorph, or reptile-like, ancestor. After the first fully terrestrial tetrapods evolved, one of their lineages split into the synapsids (the line leading to mammals) and the diapsids (the line leading to reptiles, including birds). The synapsids and the diapsids diverged about 320 million years ago, in the mid-Carboniferous period. The mammals themselves are the only survivors of the synapsid line. Humans and other apes are Old World monkeys. There is a concerted social and religious effort to deny evidence which connects humans to their ancestors and fellow extant simians, but there is no way to naturally define the monkeys while excluding humans and other apes. Humans did not evolve from either of the living species of chimpanzees or any other living species of apes. Humans and chimpanzees did, however, evolve from a common ancestor. This most recent common ancestor of living humans and chimpanzees would have lived between 5 and 8 million years ago.
=== Bone marrow barrier === The blood vessels of the bone marrow constitute a barrier, inhibiting immature blood cells from leaving the marrow. Only mature blood cells contain the membrane proteins, such as aquaporin and glycophorin, that are required to attach to and pass the blood vessel endothelium. Hematopoietic stem cells may also cross the bone marrow barrier, and may thus be harvested from blood.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.